(Q36526275)

14 August 2017

Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis (English)

1 reference

14 August 2017

1 reference

1 reference

3

Yair Lotan

1 reference

14 August 2017

Robert S Svatek

1

1 reference

PubMed ID

16818188

14 August 2017

Arthur I Sagalowsky

series ordinal

2

1 reference

14 August 2017

1 July 2006

1 reference

14 August 2017

1 reference

14 August 2017

24

1 reference

14 August 2017

338-343

1 reference

14 August 2017

4

1 reference

Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.025

Screening and monitoring for bladder cancer: refining the use of NMP22

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.025

A community study of bladder cancer screening by the detection of occult urinary bleeding.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.025

Detection of bladder cancer using a point-of-care proteomic assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.025

Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.025

Cost-effectiveness of whole-body CT screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.025

An economic rationale for prostate cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.025

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.025

Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.025

Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.025

NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.025

Controversies in prostate cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.025

Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.025

Hematuria home screening: repeat testing results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.025

Utilization of nuclear matrix proteins for cancer diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.025

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UROLONC.2005.11.025

1 reference

14 August 2017

1 reference

PubMed ID

16818188